Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
140.87
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
53
54
Next >
Trillion-Dollar Threshold: The Next 3 Stocks Ready to Rise
March 06, 2024
With a trillion-dollar valuation in sight, these three growth companies have stocks ready to rise to meet the challenge.
Via
InvestorPlace
Novo Nordisk's Semaglutide's Multi-Beneficial Effects: Weight Loss, Improved Metabolic Markers, Liver Fat Reduction in HIV-Related Liver Disease
March 06, 2024
Novo Nordisk's Semaglutide, a breakthrough in HIV and fatty liver disease research, shows a 31% average reduction in liver fat. Novo Nordisk's trial reveals significant benefits for kidney health.
Via
Benzinga
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
March 06, 2024
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it.
Via
Investor's Business Daily
Exposures
Product Safety
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
March 06, 2024
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising...
Via
Benzinga
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
March 06, 2024
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher
Via
MarketBeat
Exposures
Product Safety
What the Options Market Tells Us About Novo Nordisk
March 04, 2024
Via
Benzinga
What the Options Market Tells Us About Novo Nordisk
March 01, 2024
Via
Benzinga
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
March 06, 2024
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings.
Via
The Motley Fool
Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday
March 05, 2024
The hotly popular European pharmaceutical company continues to investigate how its most popular molecule can be used for different afflictions.
Via
The Motley Fool
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.
Via
Benzinga
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
March 05, 2024
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with semaglutide 1.0 mg compared to placebo. Impact on dialysis stocks
Via
Benzinga
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
March 05, 2024
Here's why I'm not worried.
Via
The Motley Fool
Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
February 29, 2024
Via
Benzinga
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
March 05, 2024
Novo Nordisk tested its diabetes and weight-loss drug in patients with chronic kidney disease.
Via
Investor's Business Daily
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
March 05, 2024
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
Via
The Motley Fool
Novo Nordisk Says Famed Diabetes Medicine Ozempic Reduces Risk Of Kidney Disease Progression, Data Shows
March 05, 2024
Kidney outcomes trial results by Novo Nordisk. Semaglutide 1.0 mg shows a 24% reduction in kidney disease progression, cardiovascular events, and mortality risk in type 2 diabetes and CKD.
Via
Benzinga
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
March 05, 2024
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward.
Via
InvestorPlace
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
March 05, 2024
One is a reigning champion, and the other is a burgeoning contender.
Via
The Motley Fool
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
March 05, 2024
Cramer suggested that the upcoming labor report could potentially trigger a buying opportunity, predicting stronger figures than expected by Wall Street.
Via
Benzinga
The Ozempic Diet Trend is Lifting These 2 Carnivore Stocks
March 04, 2024
The carnivore diet is back in the spotlight as people seek GLP-1 alternatives; here are two meat stocks that are moving higher on this trend
Via
MarketBeat
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
March 03, 2024
This is a close contest, and it'll go on for at least a few more rounds.
Via
The Motley Fool
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
March 03, 2024
The battle for the obesity therapies market is escalating.
Via
The Motley Fool
3 Magnificent Growth Stocks to Buy in March
March 02, 2024
These three stocks have two important common denominators: the same industry and tremendous growth prospects.
Via
The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
March 01, 2024
A favorite of both investors and analysts gets a boost from a bullish move by a pundit.
Via
The Motley Fool
Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets
March 01, 2024
Eli Lilly: BofA Securities rates it a top pick in Biopharma, with a YTD performance of +29%. Analysts highlight undervalued opportunities in heart disease, sleep apnea, and liver disease. Price target...
Via
Benzinga
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
March 01, 2024
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says.
Via
Investor's Business Daily
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
March 01, 2024
It will take a lot, but this goal isn't out of reach for these stocks.
Via
The Motley Fool
These 4 Stocks Are the "Magnificent Seven" of Healthcare
March 01, 2024
Their growth trajectories aren't as meteoric, but they're still notable.
Via
The Motley Fool
Ozempic, Wegovy Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns
March 01, 2024
The World Health Organization has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone.
Via
Benzinga
5 Investors Betting Big on Weight Watchers (WW) Stock as Oprah Backs Out
February 29, 2024
WW stock is falling lower after its earnings, adding that Oprah Winfrey would step down from the board of directors.
Via
InvestorPlace
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
53
54
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.